Patients with high CD47 expression have been shown to demonstrate poorer outcomes compared to those with low CD47 expression in several indications, including breast cancer (7, 41), HNSCC (9) and acute myeloid leukemia (42). Here, CD47 is linked to acute myeloid leukemia.